Trade name:

The international name:
Alfuzozin (Alfuzosin)

Group Affiliation:
Alpha 1-blocker

Description of the active substance (INN):

Dosage form:
coated tablets, tablets with prolonged action, prolonged action tablets coated

Mode of action:
Alpha 1-adrenoceptor blocker (mainly in the zone of the prostate, urethra and bladder of the triangle). Reduces pressure in the urethra and reduces resistance to the current urine facilitates urination and eliminates dysuria, including with prostatic hyperplasia. In therapeutic doses has no effect on alpha 1-adrenergic receptors of the vessels.

Functional urination disorders in benign prostatic hyperplasia.

Hypersensitivity, orthostatic hypotension (history), simultaneous reception of other alpha-adrenoblokatorov.C caution. Coronary heart disease, chronic renal failure, concomitant therapy antihypertensive drugs, advanced age (older than 75 years).

Adverse effects:
On the part of the digestive system: dry mouth, nausea, pain in the epigastrium, diarrhea. On the part of the nervous system: headache, dizziness, weakness, drowsiness, asthenia syndrome with SSS by: tachycardia, orthostatic hypotension, in patients with coronary heart disease - exacerbation of symptoms of angina. Allergic reactions: skin rash, itching. Other: tinnitus, edema, hyperemia kozhi.Peredozirovka. Symptoms: blood pressure reduction. Treatment: Introduction vasoconstrictive means, solutions of high molecular substances, the increase in BCC, dialysis - is ineffective.

Dosage and administration:
Inside, not liquid, 5 mg in the morning and evening, begin treatment with an evening reception. Daily dose - 10 mg. Elderly or patients receiving antihypertensive therapy, prescribed at 5 mg / day, at night, if necessary, dose increased to 10 mg / day (no more).

Not compatible with other alpha1-blockers. Strengthens effect of antihypertensive drugs, including BCCI and general anesthetics (possible unstable blood pressure during anesthesia)